Clinical Trial

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

Name: T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis — clinical trial record (NCT07152782)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: THUNDER

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Neratinib in HER2-positive breast cancer with brain metastasis

Trial Details

NCT Number	NCT07152782
Lead Sponsor	Fudan University
Conditions	Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
Enrollment	202 participants
Start Date	2025-11
Primary Completion	2027-11 (estimated)
Study Completion	2029-11 (estimated)
Updated on ClinicalTrials.gov	2025-09-03